Search Results - "Morrison, Gilmour"

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs by Patsalos, Philip N., Szaflarski, Jerzy P., Gidal, Barry, VanLandingham, Kevan, Critchley, David, Morrison, Gilmour

“…Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox‐Gastaut syndrome or Dravet syndrome in…”
Get full text

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects by Taylor, Lesley, Gidal, Barry, Blakey, Graham, Tayo, Bola, Morrison, Gilmour

“…Background A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and…”
Get full text

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment by Taylor, Lesley, Crockett, Julie, Tayo, Bola, Morrison, Gilmour

“…The pharmacokinetics and safety of a single oral dose of 200‐mg plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution…”
Get full text

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects by Crockett, Julie, Critchley, David, Tayo, Bola, Berwaerts, Joris, Morrison, Gilmour

“…Objective The pharmacokinetics (PK) and safety of single oral 750‐mg doses of a plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD;…”
Get full text

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors by Lockhart, A Craig, Calvo, Emiliano, Tolcher, Anthony W, Rowinsky, Eric K, Shackleton, Gareth, Morrison, J Gilmour, Rafi, Rezvan, VerMeulen, Wendy, Rothenberg, Mace L

“…The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase…”
Get full text

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects by Morrison, Gilmour, Crockett, Julie, Blakey, Graham, Sommerville, Kenneth

“…GW Pharmaceuticals’ formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox‐Gastaut and…”
Get full text

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment by Tayo, Bola, Taylor, Lesley, Sahebkar, Farhad, Morrison, Gilmour

“…Introduction As patients who receive cannabidiol (CBD) may have co-existing renal morbidities, it is important to understand whether dose adjustments are…”
Get full text

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome by Devinsky, Orrin, Patel, Anup D, Thiele, Elizabeth A, Wong, Matthew H, Appleton, Richard, Harden, Cynthia L, Greenwood, Sam, Morrison, Gilmour, Sommerville, Kenneth

“…OBJECTIVETo evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet…”
Get full text

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam by VanLandingham, Kevan E., Crockett, Julie, Taylor, Lesley, Morrison, Gilmour

“…We investigated the effects of cannabidiol (CBD; 21‐day maintenance dose) on the pharmacokinetics (PK) of clobazam (CLB) and monitored the safety of CBD (or…”
Get full text

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials by Devinsky, Orrin, Thiele, Elizabeth A, Wright, Stephen, Checketts, Daniel, Morrison, Gilmour, Dunayevich, Eduardo, Knappertz, Volker

“…Objective The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized…”
Get full text

Correction to: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects by Taylor, Lesley, Gidal, Barry, Blakey, Graham, Tayo, Bola, Morrison, Gilmour

“…Page 1065, Discussion, Single and Multiple Dose CBD PK, column 2 - the equation that read:…”
Get full text

A Phase I, Randomized, Double.Blind, Placebo.Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects by Taylor, Lesley, Gidal, Barry, Blakey, Graham, Tayo, Bola, Morrison, Gilmour

“…Background A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and…”
Get full text

Drug-drug Interaction (DDI) Studies with Coadministration of Cannabidiol (CBD) and Clobazam (CLB), Valproate (VPA), Stiripentol (STP) or Midazolam (MDZ) in Healthy Volunteers (HVTs) and Adults with Epilepsy (S3.003) by Szaflarski, Jerzy, Patsalos, Philip, Gidal, Barry, VanLandingham, Kevan, Critchley, Dave, Morrison, Gilmour

“…Abstract only…”
Get full text

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy by Ben-Menachem, Elinor, Gunning, Boudewijn, Arenas Cabrera, Carmen María, VanLandingham, Kevan, Crockett, Julie, Critchley, David, Wray, Louise, Tayo, Bola, Morrison, Gilmour, Toledo, Manuel

“…Background In recent randomized, placebo-controlled, phase III trials, highly purified cannabidiol demonstrated efficacy with an acceptable safety profile in…”
Get full text

Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy by Critchley, David, Szaflarski, Jerzy, Patsalos, Philip, Gidal, Barry, VanLandingham, Kevan, Morrison, Gilmour

Get full text

Exposure-Response Analysis of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox–Gastaut Syndrome (P1.271) by Morrison, Gilmour, Sardu, Maria Luisa, Rasmussen, Christian Hove, Sommerville, Kenneth, Roberts, Claire, Blakey, Graham E.

“…Abstract only…”
Get full text

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome by Roboz, Gail J., Khoury, H. Jean, Jabbour, Elias, Session, Wilena, Ritchie, Ellen K., Miao, Harry, Faderl, Stefan, Zheng, Wei, Feldman, Eric J., Arellano, Martha, Morrison, J. Gilmour, Ravandi, Farhad

“…Abstract There is no effective treatment for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a phase I dose…”
Get full text

A dose ranging safety and pharmacokinetic study of cannabidol (CBD) in children with Dravet syndrome (GWPCARE1) (P4.108) by Patel, Anup, Devinsky, Orrin, Thiele, Elizabeth, Wong, Mathew, Appleton, Richard, Harden, Cynthia, Sommerville, Ken, Greenwood, Sam, Morrison, Gilmour

“…Abstract only…”
Get full text

Abstract CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding by Siu, Lillian L., De Bono, Johann, Wisinski, Kari B., Higano, Celestia S., Cook, Natalie, De Miguel Luken, Maria Jose, Kumar, Rajiv, Lang, Joshua, Chatta, Gurkamal S., Tolaney, Sara M., Symeonides, Stefan M., Morrison, Gilmour, Mitchell, Patrick D., Brooks, David G., Shapiro, Geoffrey I.

“…Abstract Background: A frequent mechanism of dysregulation of the PI3K/AKT/mTOR pathway, commonly altered in cancer, is loss of function of the tumour…”
Get full text

Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy by STALLARD, S, GILMOUR MORRISON, J, GEORGE, W. D, KAYE, S. B

“…Response to cytotoxic agents is assumed to be related to the concentration of drug achieved within tumour tissue. It is also often assumed that, given similar…”
Get full text